Clinical Trial Update: Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy [Phase 2]

View source ↗

Summary

Phase 2 study of REGN4461, a leptin receptor agonist antibody, in patients with Generalized Lipodystrophy has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Lipodystrophy

Drugs mentioned

• REGN4461

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Generalized Lipodystrophy | Phase 2 | Status: COMPLETED | Results posted: 2025-02-25